Clinical trials: Prostate Adenocarcinoma
Metastatic Cancer, Prostate Cancer
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone.
- Trial name
- NCT00634582
- Testing
- paricalcitol, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Prostate Cancer
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Interstitial brachytherapy uses radioactive material placed directly into or near a tumor to kill tumor cells.
- Trial name
- NCT00063882
- Testing
- Brachytherapy (100/110), Brachytherapy (125/145), External Beam Radiation Therapy
- Where
- 170 sites in United States, Canada
- Volunteers
- 588 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis)
Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making
Development of an Intelligent System Integrating Preoperative Imaging and Real-Time Intraoperative Metabolic Feedback to Dynamically Optimize Biopsy core Placement for Individualized Precision Sampling.
- Trial name
- NCT07856017
- Where
- 4 sites in China
- Volunteers
- 90 people
- Sponsor
- Shanghai Zhongshan Hospital
Prostate Adenocarcinoma
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
This phase II trial studies how well apalutamide works in treating patients with prostate cancer who are in active surveillance. Testosterone can cause the growth of prostate cancer cells.
- Trial name
- NCT02721979
- Testing
- Apalutamide, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Washington
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer
This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. Cinacalcet hydrochloride may be effective in lowering prostate-specific antigen (PSA) levels in patients with…
- Trial name
- NCT01054079
- Testing
- laboratory biomarker analysis, quality-of-life assessment, questionnaire administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma)
CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer
This is a prospective, randomized, open-label, phase II multicenter clinical trial evaluating the efficacy and safety of radical prostatectomy in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) who…
- Conditions
- Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- CONVERT-HB1 (NCT07268794)
- Testing
- Androgen Deprivation Therapy (ADT), Docetaxel, PARP Inhibitors and Other Systemic Agents
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Fudan University
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
This phase II trial studies how well testosterone (enanthate or cypionate) and olaparib work in treating patients with prostate cancer that has progressed despite hormonal therapy.
- Trial name
- NCT03516812
- Testing
- Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Washington
Metastatic Cancer, Prostate Cancer
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01160705
- Testing
- docetaxel, RNA analysis, reverse transcriptase-polymerase chain reaction
- Where
- 5 sites in Ireland
- Volunteers
- 73 people
- Sponsor
- Cancer Trials Ireland
Prostate Cancer (Adenocarcinoma), Bladder Cancer
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
This trial tests if AI can help make medical info clear and readable. Many patients struggle to find medical informations that easy to read and understand from verified medical sources.
- Conditions
- Prostate Cancer (Adenocarcinoma), Bladder Cancer, Kidney Cancers, Testis Cancer
- Trial name
- NCT07568444
- Testing
- Pub2Post
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Prostate Cancer
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002633
- Testing
- bicalutamide, buserelin, flutamide
- Where
- 15 sites in Canada
- Volunteers
- 361 people
- Sponsor
- NCIC Clinical Trials Group
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel
Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00096499
- Testing
- ispinesib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00096304
- Testing
- docetaxel, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical University of South Carolina
Prostate Cancer (Adenocarcinoma)
68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of…
- Trial name
- NCT06612580
- Testing
- 68Ga-AAZTA-NI-093
- Where
- China
- Volunteers
- 10 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Prostate Cancer
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
RATIONALE: Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00046826
- Testing
- docetaxel, estramustine phosphate sodium, thalidomide
- Where
- 2 sites in United States
- Sponsor
- Nuvance Health
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocking hormone production…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06616155
- Testing
- Biopsy, Biospecimen Collection, Bone Scan
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Adenocarcinoma, Radiation Toxicity
Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer
Hypo-Combi Trial: A Prospective Phase I/II Study of Combined Hypofractionated External Beam Radiation Therapy (EBRT) plus Interstitial High-Dose-Rate Brachytherapy (HDR-BT) for Intermediate/High Risk Prostate Cancer
- Trial name
- Hypo-Combi (NCT05003752)
- Testing
- External beam radiation therapy, High-dose-rate brachytherapy, Goserelin 10.8 mg
- Where
- Cyprus
- Volunteers
- 40 people
- Sponsor
- German Oncology Center, Cyprus
Prostate Cancer
Proton Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT01045226
- Testing
- Proton Beam Radiation Therapy, Quality-of-Life assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
This phase II trial studies how well durvalumab and olaparib work in treating prostate cancer in men predicted to have specific genetic mutations (a high neoantigen load).
- Trial name
- NCT04336943
- Testing
- Durvalumab, Olaparib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Carcinomas, Amyloidosis
B-Receptor Signaling in Cardiomyopathy
We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether…
- Conditions
- Carcinomas, Amyloidosis, Anal Cancer, Anemia
- Trial name
- NCT01135849
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Daniel Bernstein